



Correction to: Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment

Peter Zannikos¹ · Bhavna Solanki² · Marc De Meulder³ · Philipp Badorrek⁴ · Jens M. Hohlfeld^{5,6} · Jaskaran Singh⁷

Published online: 5 August 2023

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023

Correction to: Clinical Pharmacokinetics

<https://doi.org/10.1007/s40262-023-01273-z>

In Table 1 of this article, an incorrect footnote was inserted, and it should have been ‘Values are mean (standard deviation) except for t_{\max} for which the values are median (minimum and maximum values)’.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40262-023-01273-z>.

✉ Peter Zannikos
pnzannikos@gmail.com

Bhavna Solanki
bsolanki@its.jnj.com

Marc De Meulder
mdmeulde@its.jnj.com

Philipp Badorrek
philipp.badorrek@item.fraunhofer.de

Jens M. Hohlfeld
jens.hohlfeld@item.fraunhofer.de

Jaskaran Singh
jsingh@neurocrine.com

¹ Janssen R&D, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA

² Janssen R&D, 6050 Paseo Carreta, Carlsbad, CA 92009, USA

³ Janssen R&D, Turnhoutseweg 30, Beerse, 2340 Antwerp, Belgium

⁴ Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine, Feodor-Lynen-Str. 15, 30625 Hannover, Germany

⁵ Department of Respiratory Science, Fraunhofer Institute for Toxicology and Experimental Medicine, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

⁶ German Center for Lung Research (DZL), BREATH, Hannover, Germany

⁷ Neurocrine Bioscience, Inc, 12780 El Camino Real, San Diego, CA 92130, USA

Table 1 Esketamine and noresketamine pharmacokinetic parameters after self-administration of 56 mg nasal esketamine by patients with allergic rhinitis (Cohort 1) and healthy subjects before and after daily nasal administration of 200 µg of mometasone for 16 days (Cohort 2)

	Rhinitis patients ^a (<i>n</i> = 21)	Healthy subjects after mometasone pretreat- ment (<i>n</i> = 23)	Healthy subjects before mometasone pretreatment (<i>n</i> = 24)	Geometric mean ratio (90% CI)	
				Rhinitis patients ^a vs healthy subjects before mometasone pretreatment	Healthy subjects after vs before mometasone pretreatment
Esketamine					
<i>t</i> _{max} (h)	0.37 (0.20–1.50)	0.67 (0.37–1.25)	0.54 (0.37–1.52)	–	–
<i>C</i> _{max} (ng/mL)	87.3 (26.1)	70.1 (26.3)	71.8 (26.4)	1.21 (1.02, 1.44)	0.96 (0.85, 1.09)
AUC _{last} (ng*h/mL)	249 (69.0)	202 (44.9)	220 (61.6)	1.14 (0.98, 1.32)	0.93 (0.86, 1.02)
AUC _∞ (ng*h/mL)	242 (69.4) ^b	210 (41.0) ^c	230 (62.7)	1.04 (0.88, 1.24)	0.92 (0.84, 1.00)
<i>t</i> _{1/2} (h)	7.1 (2.1) ^b	7.8 (1.4) ^c	8.0 (2.1)	–	–
Noresketamine					
<i>t</i> _{max} (h)	1.52 (0.83–5.97)	1.25 (0.67–4.03)	1.53 (0.67–3.98)	–	–
<i>C</i> _{max} (ng/mL)	134 (61.7)	151 (57.6)	139 (51.4)	0.91 (0.72, 1.16)	1.09 (0.98, 1.22)
AUC _{last} (ng*h/mL)	785 (322)	795 (234)	778 (245)	0.98 (0.80, 1.21)	1.05 (0.98, 1.12)
AUC _∞ (ng*h/mL)	843 (342)	850 (252)	835 (269)	0.99 (0.81, 1.22)	1.05 (0.98, 1.12)
<i>t</i> _{1/2} (h)	8.2 (2.2)	8.2 (1.9)	8.2 (1.8)	–	–

Values are mean (standard deviation) except for *t*_{max} for which the values are median (minimum and maximum values)

AUC_∞ area under plasma concentration time curve from time 0 to infinity, AUC_{last} under plasma concentration time curve from time 0 to the time of the last measurable concentration, CI confidence interval, *C*_{max} maximum concentration, *t*_{1/2} terminal elimination half-life, *t*_{max} time to maximum concentration

^aWithout oxymetazoline pretreatment

^b17 patients with allergic rhinitis

^c21 healthy subjects